[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Wensheng Qu\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":43},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":5},"100660012","phase-4-acute-treatment-of-vestibular-migraine-by-rimegepant-100660012",false,"NCT07871097","Acute Treatment of Vestibular Migraine by Rimegepant","Efficacy of Rimegepant in the Treatment of Acute Vestibular Migraine -- Multicenter, Prospective, Cross-design, Randomized, Placebo-controlled Study","VM-rime","Inclusion Criteria:\n\n1. Age 18-60 years, male or female.\n2. Diagnosis of vestibular migraine according to the Bárány Society criteria.\n3. ≥4 episodes of characteristic vestibular symptoms in the past year, each of moderate to severe intensity and lasting \\>2 hours (without intervention).\n4. Signed informed consent obtained from the participant.\n\nExclusion Criteria:\n\n1. Presence of other disorders causing acute vestibular symptoms (e.g., Ménière's disease, otitis media).\n2. Coexisting non-vertiginous dizziness (e.g., dizziness due to panic disorder), unless the patient can clearly distinguish these episodes from vestibular-migraine attacks.\n3. Severe hepatic dysfunction (ALT and\u002For AST \\>3× upper limit of normal) or renal impairment (creatinine clearance \\\u003C30 mL\u002Fmin).\n4. Severe cardiovascular or cerebrovascular disease.\n5. Alcohol abuse or substance abuse.\n6. Known pregnancy or lactation, or a positive pregnancy test prior to randomization.\n7. Contraindication or hypersensitivity to any medications used in the study.\n8. Initiation or dose adjustment of any preventive migraine therapy within 3 months prior to study drug administration.\n9. Use of any other anti-vertigo or analgesic medication within 6 hours before study drug administration.\n10. Participation in another interventional clinical study that could affect outcome assessment.\n11. Any other condition that, in the investigator's judgment, makes the participant unsuitable for the study or poses significant risk.","ALL","18 Years","60 Years",{"count":21,"type":22},80,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","To evaluate whether rimegepant improves acute vestibular symptoms and accompanying discomforts in patients with vestibular migraine.",[28],"Vestibular Migraine",[30],"remigepant","RECRUITING","2026-10-07",{"date":34,"type":35},"2026-10-13","ACTUAL",{"date":37,"type":35},"2025-12-01",{"date":39,"type":22},"2027-12-01",{"name":41,"class":42},"Wensheng Qu","OTHER",""]